Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Could A Robot Be Used To Grow New Human Cells? The UK Regulator Thinks So

Executive Summary

Stem cell therapies have the potential to treat a vast range of conditions, from forms of blindness to Parkinson’s disease, but manufacturing these products is difficult. The UK medtech regulator is exploring whether a robot could solve this problem.

You may also be interested in...



Gene Therapy HTA: How Do The European, Australian And Canadian Systems Shape Up?

A report comparing the health technology assessment methods used in nine European countries, Australia and Canada found that England has the most favorable reimbursement landscape for gene therapies – but outlined several areas for improvement across the board.

EU Orphan Drug Law Reform Will See Innovation Drop By 12%, Industry Warns

The European Commission’s proposals to overhaul the EU pharma legislation, which will see some orphan drug incentives cut, would cause a “significant dip in innovation,” according to number crunching from pharma industry association EFPIA.

Tackling AMR: OECD Says Greater Investment Needed In Later-Stage Drug R&D

Governments should increase financial resources for novel antimicrobial drug candidates in the later stages of development and tackle shortages of existing, underused antibiotics to combat antimicrobial resistance, says a new report from the OECD.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel